Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 4/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22861121 | 0.83 | HMGCR (0.42) | HMGCRATM | |
| SCHEMBL171441 | 0.82 | ALDH1A1 (0.52) | TAAR1ALDH1A1SLC6A4CALM1 | |
| SCHEMBL25774449 | 0.82 | HMGCR (0.49) | HMGCRATM | |
| SCHEMBL9879684 | 0.82 | HMGCR (0.53) | HMGCRATM | |
| SCHEMBL22861019 | 0.79 | PTGS2 (0.41) | CA1CA2ALDH1A1CALM1 | |
| SCHEMBL20821162 | 0.78 | CALM1 (0.56) | TAAR1CALM1 | |
| SCHEMBL20285804 | 0.78 | CA1 (0.42) | CA1CA2ALDH1A1CALM1 | |
| SCHEMBL23511272 | 0.78 | LMNA (0.38) | HMGCRTAAR1ALDH1A1 | |
| SCHEMBL3807248 | 0.76 | ALDH1A1 (0.53) | CA1CA2ALDH1A1 | |
| SCHEMBL278798 | 0.76 | ALDH1A1 (0.61) | CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145050-A1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | NodThera Limited (GB) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145050-A1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | NLRP3, NOD1, IL1B | HMGCR 4449/4885TAAR1 4360/4885CA1 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.